Drug for advanced pancreatic cancer after prior treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug for pancreatic cancer that has spread or come back after at least one prior treatment. The drug targets a protein on cancer cells to help stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has spread or come back after at least one round of chemotherapy.
- You are 18 years or older.
- You are able to take care of yourself (ECOG score 0-2) and have adequate organ function.
- You have at least one tumor that can be measured by scans.
- You must not have certain eye conditions, active infections, or other serious health issues.
- You must agree to use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a new medicine that targets cancer cells with specific proteins, to see if it can stop the growth of advanced pancreatic and breast cancer when other treatments have stopped working. It is an umbrella study, which means different protein-matched drugs are tested for different cancer types.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new drug called sacituzumab tirumotecan (also known as MK-2870) for people with advanced small bowel cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target a protein called TROP2 on cancer cells and deliver a chemo-like payload directly to them, which may help shrink or control the tumor.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.